MRK · News · 20261102N

Regulatory Approval Milestones

Merck & Co., Inc. · 2026-11-02 · Importance 31 · Surprise 42

The FDA accepted two supplemental New Drug Applications for Merck’s oral HIV medicine IDVYNSO. The applications are under review. An FDA action date is set for 2027.

Key facts

• The FDA accepted two supplemental New Drug Applications for Merck's oral HIV medicine IDVYNSO, with an action date set in 2027. source